Feb 10, 2009 - Cubist Pharmaceuticals, Inc. today announced that it has received a Paragraph IV Certification Notice Letter from Teva Parenteral Medicines, Inc. notifying Cubist that TPM had submitted an Abbreviated New Drug Application to the US Food and Drug Administration (FDA) for approval to market a generic version of CUBICIN (daptomycin for injection).
The details can be read here.
No comments:
Post a Comment